J7503 Insurance Policy Changes

HCPCS J7503 is officially defined as "Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg." HCPCS J7503 is referenced in 2 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J7503 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Aug 17, 2026Medium impact
Fetal Echocardiography and Magnetocardiography (CPB 0106, reviewed 2026-03-26)
Aetna considers fetal echocardiograms, Doppler and color flow mapping after 12 weeks gestation medically necessary for listed indications. These include a mother with type 1 diabetes or pregestational type 2 diabetes on insulin during the first trimester, a mother with systemic lupus erythematosus, a fetal nuchal translucency of 3.5 mm or greater in the first trimester, pregnancies conceived by IVF or ICSI, monochorionic twins, suspected twin-twin transfusion syndrome, suspected or documented fetal arrhythmia, suspected or known fetal chromosomal abnormalities, single umbilical artery, persistent right umbilical vein, non-immune fetal hydrops or unexplained severe polyhydramnios, and seizure disorders in members even if they are not taking anti-seizure medication. Fetal exposure to anti-seizure medications, excessive alcohol, lithium, paroxetine or retinoids is also a listed indication. Repeat studies are covered for listed findings and for fetal surveillance of anti-Ro (SSA) or anti-La (SSB) exposure, which may be repeated every 1 to 2 weeks starting at 16 weeks gestation through 28 weeks, then every other week until 32 weeks. Fetal echocardiograms for advanced maternal age screening, gestational diabetes even if requiring insulin after the first trimester, modafinil exposure, selective serotonin reuptake inhibitors except paroxetine, tacrolimus, a tortuous ductus arteriosus, and suspected cystic fibrosis are experimental, investigational or unproven. Fetal magnetocardiography and deep learning-based models for diagnosing fetal arrhythmia are also experimental, investigational or unproven.
Aetna · Identified Aug 13, 2026Medium impact
Erectile Dysfunction and Peyronie's Disease (CPB 0007, reviewed 2026-07-29)
Aetna considers the diagnosis and treatment of erectile dysfunction medically necessary under the criteria in its policy, including self-administered injectable medications, the external penile vacuum pump as a physician-prescribed durable medical equipment alternative to other therapies, and implantable penile prostheses when the documented criteria are met. Surgical correction of Peyronie's disease, such as plaque excisions, venous graft patching, tunica plication or the Nesbit tuck, is medically necessary for members who have the condition for 12 or more months with significant morbidity and have failed conservative medical treatment. Many other treatments, including extracorporeal shock wave therapy and testosterone injection for Peyronie's disease and stem cell therapy for erectile dysfunction, are considered experimental, investigational, or unproven.

Watch J7503

Get one email when a payer policy names J7503, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

REFERENCE DATA

Payers with rules2

Payers requiring prior auth2

Fidelis Care · Effective November 1, 2026
Prior authorization required
Fidelis Care Metal-Level Products authorization grid

FREQUENTLY ASKED QUESTIONS

Does AmeriHealth Caritas require prior authorization for J7503?

AmeriHealth Caritas lists J7503 on AmeriHealth Caritas Louisiana prior authorization service list for medicaid managed plans. Verify with the payer before scheduling.

Does Fidelis Care require prior authorization for J7503?

Fidelis Care lists J7503 on Fidelis Care Metal-Level Products authorization grid for exchange plans (list dated November 1, 2026). Verify with the payer before scheduling.

What insurance policy changes affect HCPCS J7503?

There are 2 tracked policy changes affecting HCPCS J7503, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS J7503?

Payers that have issued tracked updates for HCPCS J7503 include: Aetna.

How do I get notified when HCPCS J7503 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS J7503. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for HCPCS J7503?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

See every payer rule for J7503

Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for J7503 in one place.

See every payer rule

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Fetal Echocardiography and Magnetocardiography (CPB 0106, reviewed 2026-03-26)

Erectile Dysfunction and Peyronie's Disease (CPB 0007, reviewed 2026-07-29)

Prior authorization required